257 related articles for article (PubMed ID: 22265328)
1. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Vitale A; Boccagni P; Kertusha X; Zanus G; D'Amico F; Lodo E; Pastorelli D; Ramirez Morales R; Lombardi G; Senzolo M; Burra P; Cillo U
Transplant Proc; 2012 Sep; 44(7):1989-91. PubMed ID: 22974889
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Schmid I; Häberle B; Albert MH; Corbacioglu S; Fröhlich B; Graf N; Kammer B; Kontny U; Leuschner I; Scheel-Walter HG; Scheurlen W; Werner S; Wiesel T; von Schweinitz D
Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
[TBL] [Abstract][Full Text] [Related]
10. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
11. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
14. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Bhoori S; Toffanin S; Sposito C; Germini A; Pellegrinelli A; Lampis A; Mazzaferro V
J Hepatol; 2010 May; 52(5):771-5. PubMed ID: 20347502
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
17. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.
Lee JO; Kim DY; Lim JH; Seo MD; Yi HG; Oh DY; Im SA; Kim TY; Bang YJ
J Gastroenterol Hepatol; 2009 May; 24(5):800-5. PubMed ID: 19175825
[TBL] [Abstract][Full Text] [Related]
18. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
[TBL] [Abstract][Full Text] [Related]
20. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Di Benedetto F; Berretta M; De Ruvo N; Tarantino G; D'Amico G; Ballarin R; Iemmolo RM; Gerunda GE
J Surg Oncol; 2012 Jan; 105(1):111-2. PubMed ID: 21792942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
